Mark Schoenberg Sells 10,000 Shares of Urogen Pharma (NASDAQ:URGN) Stock

Urogen Pharma (NASDAQ:URGN) insider Mark Schoenberg sold 10,000 shares of Urogen Pharma stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $40.00, for a total transaction of $400,000.00. Following the completion of the sale, the insider owned 119,763 shares in the company, valued at $4,790,520. This trade represents a 7.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mark Schoenberg also recently made the following trade(s):

• On Monday, June 22nd, Mark Schoenberg sold 10,000 shares of Urogen Pharma stock. The stock was sold at an average price of $35.01, for a total transaction of $350,100.00.
• On Monday, June 8th, Mark Schoenberg sold 5,222 shares of Urogen Pharma stock. The stock was sold at an average price of $27.30, for a total transaction of $142,560.60.

Urogen Pharma Stock Performance

Urogen Pharma stock traded down $1.67 during mid-day trading on Friday, reaching $38.56. The company’s stock had a trading volume of 1,281,162 shares, compared to its average volume of 656,502. The company has a market capitalization of $1.88 billion, a price-to-earnings ratio of -14.02 and a beta of 1.56. Urogen Pharma has a 12 month low of $13.79 and a 12 month high of $40.35. The business’s 50 day simple moving average is $31.28 and its 200 day simple moving average is $24.43.

Urogen Pharma (NASDAQ:URGN) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.01. The business had revenue of $50.96 million for the quarter, compared to the consensus estimate of $44.83 million. As a group, sell-side analysts expect that Urogen Pharma will post -0.88 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of URGN. JPMorgan Chase & Co. raised its stake in Urogen Pharma by 36.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 534,545 shares of the company’s stock worth $10,664,000 after purchasing an additional 144,181 shares in the last quarter. Hennion & Walsh Asset Management Inc. grew its position in shares of Urogen Pharma by 148.4% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 161,924 shares of the company’s stock worth $3,792,000 after purchasing an additional 96,741 shares in the last quarter. SG Americas Securities LLC grew its position in shares of Urogen Pharma by 19.0% during the 4th quarter. SG Americas Securities LLC now owns 1,377,647 shares of the company’s stock worth $32,264,000 after purchasing an additional 220,264 shares in the last quarter. Rice Hall James & Associates LLC increased its holdings in shares of Urogen Pharma by 8.8% during the fourth quarter. Rice Hall James & Associates LLC now owns 281,876 shares of the company’s stock worth $6,602,000 after purchasing an additional 22,733 shares during the period. Finally, Elmind Capital LP bought a new position in shares of Urogen Pharma during the fourth quarter worth approximately $2,342,000. Institutional investors and hedge funds own 91.29% of the company’s stock.

Wall Street Analysts Forecast Growth

URGN has been the subject of several recent research reports. Oppenheimer reissued an “outperform” rating on shares of Urogen Pharma in a research report on Tuesday, June 2nd. UBS Group reiterated a “buy” rating on shares of Urogen Pharma in a research note on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Urogen Pharma in a report on Monday, April 20th. Jefferies Financial Group raised shares of Urogen Pharma to a “strong-buy” rating in a research note on Friday, April 24th. Finally, D. Boral Capital restated a “buy” rating and set a $33.00 target price on shares of Urogen Pharma in a report on Tuesday, March 31st. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $39.50.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.